Tirzepatide for Patients with Obesity and Obstructive Sleep Apnea

In two randomized trials, this drug improved polysomnographic and clinical outcomes.

Weight reduction is one of several approaches to treating patients with obstructive sleep apnea (OSA). To examine whether tirzepatide — the glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) receptor agonist that is U.S. FDA–approved for treating patients with obesity — is an effective agent for OSA, researchers conducted two industry-sponsored, multicenter, randomized trials.

One trial involved 234 patients with obesity and moderate-to-severe OSA who were unwilling to use — or unable to tolerate — positive airway pressure (PAP) treatment. The other trial involved 235 patients with obesity who were using PAP but still had moderate-to-severe OSA. At baseline, mean body-mass index was 39 kg/m²; patients with diabetes were…

Reviewing Author

Allan S. Brett, MD

Disclosures

Nothing to disclose

Allan S. Brett, MD

Disclosures

Nothing to disclose

Tirzepatide for Patients with Obesity and Obstructive Sleep Apnea

Topics

Reviewing Author